12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of '12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis'. Together they form a unique fingerprint.

Medicine & Life Sciences